SynthesisFrontiers in surgery2026
Preoperative inflammation-based biomarkers and postoperative pulmonary complications after lung resection for lung cancer: a systematic review with selective exploratory quantitative synthesis.
Synthesis in Frontiers in surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Postoperative pulmonary complications (PPCs) remain a source of morbidity after lung resection for lung cancer. Several preoperative inflammation-based biomarkers have been investigated as potential risk indicators, but the literature remains methodologically heterogeneous across biomarker types, analytic scales, and outcome definitions. Methods: Following PRISMA 2020 guidelines, we searched PubMed, Web of Science, Scopus, Embase, and the Cochrane Library from inception to March 20, 2026. We included original studies evaluating preoperative inflammation-based biomarkers in patients undergoing lung resection for lung cancer if PPCs or extractable pulmonary complication outcomes were reported. PPCs were prespecified as the primary outcome framework, and postoperative pneumonia (POP) was analyzed as a major subtype. Because of substantial heterogeneity across biomarkers, analytical approaches, and outcome definitions, the evidence was synthesized at the study level, with selective exploratory quantitative syntheses performed only when clinical comparability was acceptable. Results: Eight studies were included, comprising seven retrospective cohorts and one prospective cohort. Quantitative synthesis was exploratory because biomarker selection, analytic scale, and pulmonary outcome definitions varied substantially across studies. Pooled analyses based on extractable effect estimates were generally unstable and highly heterogeneous; for example, the biomarker-specific NLR analysis was not significant (OR 1.53, 95% CI 0.79-2.99; I Conclusions: Selected preoperative inflammation-based biomarkers, particularly CRP, SII, and NLR, may be associated with postoperative pulmonary morbidity after lung cancer resection. However, the literature is dominated by retrospective studies and marked methodological heterogeneity, precluding a single robust pooled inference. Prospective biomarker-specific studies with standardized pulmonary outcome definitions are needed before these markers can be considered for perioperative risk stratification. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420261356969, PROSPERO CRD420261356969.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.